|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||30.65 - 30.86|
|52 Week Range||30.22 - 50.10|
|PE Ratio (TTM)||27.65|
|Dividend & Yield||0.31 (1.02%)|
|1y Target Est||31.62|
Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Dr. Reddy’s Laboratories Limited concerning possible violations of federal securities laws.
SAN DIEGO, Aug. 12, 2017 /PRNewswire/ -- Shareholder rights law firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Dr. Reddy's Laboratories Ltd. (RDY) and certain of its officers. On November 6, 2015, Dr. Reddy's reported that the Company received a "warning letter" from U.S. regulators over inadequate quality controls at three manufacturing plants producing drugs for cancer and other diseases. The next trading day, on November 9, the Company held an investor conference call to discuss the warning letter. On the call, it was further revealed that it was not just the three facilities singled out in the warning letter that was experiencing problems. In fact, the FDA required Dr. Reddy's to implement changes for every manufacturing site the Company operated. Specifically, Dr. Reddy's disclosed to investors that the FDA found deficiencies in its documentation practices and control, laboratory testing practices, adequacy of standard operating procedures, and incident investigation practices.
Khang & Khang LLP announces that it is investigating claims against Dr. Reddy’s Laboratories Limited concerning possible violations of federal securities laws.